* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
Download Virus inactivation risk assessment: work in progress
2015–16 Zika virus epidemic wikipedia , lookup
Bovine spongiform encephalopathy wikipedia , lookup
Swine influenza wikipedia , lookup
Middle East respiratory syndrome wikipedia , lookup
African trypanosomiasis wikipedia , lookup
Leptospirosis wikipedia , lookup
Influenza A virus wikipedia , lookup
Orthohantavirus wikipedia , lookup
Antiviral drug wikipedia , lookup
Herpes simplex virus wikipedia , lookup
Ebola virus disease wikipedia , lookup
West Nile fever wikipedia , lookup
Marburg virus disease wikipedia , lookup
Hepatitis C wikipedia , lookup
Hepatitis B wikipedia , lookup
Framework for a microbiological risk assessment to assess virus safety of blood products for feed Dr Lourens Heres Question How can virus safety of blood plasma be quantified? What are the critical processes to assure virus safety and which steps are insufficiently quantified? Many examples of risk assessments Milk powder and Foot-and-Mouth-Disease No reports of disease outbreaks pasteurisations BSE: MBM, Fat, gelatine, waste water, etc… Different steps – exclusion SRM critical Severe heat inactivation Risk of introduction animal diseases Risk assessment elements Identification hazard Virus: PEDV / all porcine viruses Describing and characterization of the the pathways Exposure assessment Processes (dilution, inactivation, etc.) consumption Dose-respons assessment Pig viruses posing a risk for porcine products in feed Endemic virusses PRRSV PCV2 PPV Influenza Hepatitis E PEDV Parvo-virus … Epidemic Virusses – OIE listed Classical Swine Fever (CSF) Foot and Mouth Disease (FMD) African Swine Fever Swine Vesicular Disease (SVD) Aujesky‘s disease PEDV Coronavirusses Non-stable virus Easily inactivated Virus in blood through leakage through enterocites in intestine, or faecal contamination during blood collection Infectivity in blood not (yet) shown Infectivity of spay dried plasma not shown, and due to spray drying and storage unlikely. Collection of blood Blood from clinically healthy animals (virus dilution) Anti-coagulants centrifugation Possibilities for chemical / physical treatment filtration Spray - drying standardisation storage Heated to 80°C (thermal inactivation) Possibilities for chemical / physical treatment Inactivation during storage Risk assessment: critical Virus control along the chain killed animal: no more multiplication Log-reduction steps One or some infected animals in batch with multiple animals (pooling effect) Heat and chemical treatments Drying (heat treatment) Storage Other reduction with: splitting plasma and cells,…. Exposure Several grams of the product are consumed during different days Single hit Infectivity – Infectious Dose Max infectivity level infected animals Virus load/ml blood: PCV2 106 DNA FMDV 105,5 TCID50 PRRSV 103-4 TCID50 Infectious Dose in susceptible animals (all animals infected with:) PCV2 ~104-5 TCID50 ~103,5 TCID50 FMDV (intranasal, depending on strain) ID50 PRRSV ~105,5 TCID50 Where could a quantitative risk assessment help advantages Generic approach Understanding the principles Structured approach challenges Unknown parameters Uncertainty Variability Overestimation of risk Limitations for virus QMRA The outcome will never be a zero risk. Data from publications PCR positive or culture infectious dose or animal infectious dose Power of the experiment: numbers tested: plates, wells, or animals inoculated Amount of virus added in inactivation tests Detection limit of diagnostic tests uncertainty Lab-condition versus Field-conditions Spray driers Number of animals Safe: to overcome the nonzero risk outcomes Risk assessment on animal diseases shows that under the current control measures The probility of introduction of CSF in The Netherlands 1 per 16 years of FMDV in the US 1 per 240 years Of FMDV in Spain 1 per 40 years Risk assessments University of Minnesota APC Funded by National Pork Board Risk assessment ingredients of porcine origin Started in April Many studies, see summary next presentation J. Polo Sonac With NIZO and Wageningen-UR Validation of virus safety Different processes Different model viruses Thank you for your attention